NCT00190281

Brief Summary

To evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional US with continuous infusion of a contrast agent (SonoVue, Bracco, Italy). Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2005

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 19, 2005

Completed
Last Updated

December 13, 2005

Status Verified

March 1, 2005

First QC Date

September 13, 2005

Last Update Submit

December 12, 2005

Conditions

MalariaPyelonephritisBacterial Infections

Keywords

FUNCTIONAL STUDYCONTRAST-ENHANCED USPERFUSION

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Social security number
  • Age over 18
  • acute malaria infection or other infectious diseases
  • Inpatients
  • Signed informed consent form

You may not qualify if:

  • Pregnancy
  • Criteria of bad tolerance of infection
  • Treatment started for more than 8 hours
  • Lack of cooperation
  • History of splenectomy, hematological disease, cirrhosis with portal hypertension, splenomegaly
  • Medical treatment with beta blocker, diuretic, immunodepression drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Adult Radiology, Necker University Hospital

Paris, Île-de-France Region, 75015, France

RECRUITING

MeSH Terms

Conditions

MalariaPyelonephritisBacterial Infections

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne DiseasesNephritis, InterstitialNephritisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPyelitisMale Urogenital DiseasesBacterial Infections and Mycoses

Study Officials

  • Jean-Michel Correas, MD PhD

    NECKER UNIVERSITY HOSPITAL

    PRINCIPAL INVESTIGATOR

  • Pierre Buffet, MD PhD

    Centre Médical - Institut Pasteur

    STUDY DIRECTOR

  • Olivier Lortholary, MD PhD

    NECKER UNIVERSITY HOSPITAL

    STUDY DIRECTOR

Central Study Contacts

Olivier Lortholary, MD PhD

CONTACT

33-1-44-49-41-42olivier.lortholary@nck.ap-hop-paris.fr

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 19, 2005

Study Start

August 1, 2005

Last Updated

December 13, 2005

Record last verified: 2005-03

Locations

FR(1)